Journal Mobile Options
Table of Contents
Vol. 61, Suppl. 2, 2001
Issue release date: 2001
Oncology 2001;61(suppl 2):73–82
(DOI:10.1159/000055405)

The Predictive Value of HER2 in Breast Cancer

Piccart M. · Lohrisch C. · Di Leo A. · Larsimont D.
Institut Jules Bordet, Brussels, Belgium

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Measurement of molecular markers predictive of response to therapy should enable more selective and effective utilization of anticancer agents. The predictive value of HER2 remains a complex and inconclusive subject. In metastatic breast cancer, HER2-positive, ER-positive patients can show responses to endocrine treatment, but experience shorter time to progression and survival than HER2-negative patients. In the adjuvant setting, weak, retrospective evidence suggests that tamoxifen is potentially harmful in HER2-positive patients and that there is no benefit from prolonged tamoxifen therapy. It has not yet been demonstrated conclusively that HER2 positivity increases resistance to adjuvant cyclophosphamide, methotrexate, 5-FU (CMF), but there are indications that HER2-positive patients benefit more from adequately dosed anthracyclines than from CMF. The greatest value of HER2 as a predictive marker lies in the prediction of response to therapies that target HER2, such as Herceptin®. Patients with strongly HER2-positive breast cancer derive significant clinical benefit from single-agent and combined Herceptin therapy. HER2 testing has become an integral part of the optimal management of the breast cancer patient. Best current practice in adjuvant breast cancer therapy based on the current knowledge of the potential predictive power of HER2 constitutes not denying tamoxifen to HER2-positive, ER-positive patients or CMF to HER2-positive patients. Outside of clinical trials, adequately dosed anthracycline-based chemotherapy is the current preferred adjuvant treatment option for HER2-positive patients.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Allred DC, Clark GM, Molina R, Tandon AK, Schnitt SJ, Gilchrist KW, Osborne CK, Tormey DC, McGuire WL: Overexpression of HER-2/neu and its relationship with other prognostic factors changed during progression of in-situ to invasive breast cancer. Hum Pathol 1992a;23:974–979.
  2. Allred DC, Clark GM, Tandon AK, Molina R, Tormey DC, Osborne CK, Gilchrist KW, Mansour EG, Abeloff M, Eudey L, et al: HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma. J Clin Oncol 1992b;10:599–605.
  3. Archer SG, Eliopoulos A, Spandidos D, Barnes D, Ellis IO, Blamey RW, Nicholson RI, Robertson JF: Expression of ras p21, p53 and c-erbB-2 in advanced breast cancer and response to first-line hormonal therapy. Br J Cancer 1995;72:1259–1266.
  4. Bast RC, Jr, Ravdin P, Hayes DF, Bates S, Fritsche H, Jr, Jessup JM, Kemeny N, Locker GY, Mennel RG, Somerfield MR, for the American Society of Clinical Oncology Tumor Markers Expert Panel: 2000 Update of recommendations for the use of tumor markers in breast and colorectal cancer: Clinical Practice Guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001;19:1865–1878.
  5. Benz CC, Scott GK, Sarup JC, Johnson RM, Tripathy D, Coronado E, Shepard HM, Osborne CK: Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Treat 1992;24:85–95.
  6. Berns EM, Foekens JA, van Staveren IL, van Putten WL, de Koning HY, Portengen H, Klijn JG: Oncogene amplification and prognosis in breast cancer: relationship with systemic treatment. Gene 1995;159:11–18.

    External Resources

  7. Bianco AR, De Laurentiis M, Carlomagno C, Gallo C, Panico L, De Placido S: HER2 overexpression predicts adjuvant tamoxifen (TAM) failure for early breast cancer (EBC): complete data at 20 yr of the Naples GUN randomized trial. Proc Am Soc Clin Oncol 2000;19:75A.
  8. Borg A, Tandon AK, Sigurdsson H, Clark GM, Fernö M, Fuqua SAW, Killander D, McGuire WL: HER2/neu amplification predicts poor survival in node positive patients. Cancer Res 1990;50:6701–6707.

    External Resources

  9. Brenner TL, Adams VR: First MAb approved for the treatment of metastatic breast cancer. J Am Pharm Assoc 1999;39:236–238.
  10. Chu KC, Tarone RE, Brawley OW: Breast cancer trends of black women compared with white women. Arch Fam Med 1999;8:521–528.
  11. Clahsen PC, van de Velde CJH, Duval C, Pallud C, Mandard A-M, Delobelle-Deroide A, van den Broek L, Sahmoud TM, van de Vijver MJ: P53 protein accumulation and response to adjuvant chemotherapy in premenopausal women with node-negative early breast cancer. J Clin Oncol 1998;16:470–479.
  12. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Lieberman G, Slamon DJ: Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999;17:2639–2648.
  13. De Laurentiis M, Arpino G, Massarelli E, Carlomagno C, Ciardiello F, Tortora G, Bianco AR, De Placido S: A metanalysis of the interaction between Her2 and the response to endocrine therapy (ET) in metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 2000;19:78A.
  14. Di Leo A, Larsimont D, Beauduin M, Vindevoghel A, Michel J, Focan C, Tagnon A, Ries F, Gobert P, Closon-Dejardin MT, Dolci S, Bartholomeus S, Lobelle JP, Paesmans M, Piccart MJ: CMF or anthracycline-based adjuvant chemotherapy for node-positive (N+) breast cancer (BC) patients (PTS): 4 year results of a Belgian randomised clinical trial with predictive markers analysis. Proc Am Soc Clin Oncol 1999;18:69A.
  15. Dowsett M, Cooke T, Ellis I, Gullick WJ, Gusterson B, Ballon E, Mallon E, Walker R: Assessment of HER2 status in breast cancer: why, when and how? Eur J Cancer 2000:36:160–176.
  16. Elledge RM, McGuire WL and Osborne CK: Prognostic factors in breast cancer. Semin Oncol 1992;19:244–253.
  17. Elledge RM, Green S, Ciocca D, Pugh R, Allred DC, Clark GM, Hill J, Ravdin P, O’Sullivan J, Martino S, Osborne CK: HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology Group Study. Clin Cancer Res 1998;4:7–12.
  18. Farabegoli F, Ceccarelli C, Santini D, Baldini N, Tafurelli M, Marrano D, Trere D, Derenzini M: c-erbB-2 overexpression in amplified and non-amplified breast carcinoma samples. Int J Cancer 1999;84:273–277.
  19. Fitzgibbons PL, Page DL, Weaver D, Thor AD, Allred DC, Clark GM, Ruby SG, O’Malley F, Simpson JF, Connolly JL, Hayes DF, Edge SB, Lichter A, Schnitt SJ: Prognostic Factors in Breast Cancer. Arch Pathol Lab Med 2000;124:966–978.
  20. Giai M, Roagna R, Ponzone R, De Bortoli M, Dati C, Sismondi P: Prognostic and predictive relevance of c-erbB-2 and ras expression in node positive and negative breast cancer. Anticancer Res 1994;14:1441–1450.
  21. Gusterson BA, Gelber RD, Goldhirsch A, Price KN, Save-Soderborgh J, Styles J, Rudenstam CM, Golouh R, Reed R, et al: Prognostic importance of c-erbB-2 expression in breast cancer. J Clin Oncol 1992;10:1049–1056.
  22. Hamilton A, Piccart M: The contribution of molecular markers to the prediction of response in the treatment of breast cancer: a review of the literature on HER-2, p53 and BCL-2. Ann Oncol 2000;11:647–63.
  23. Hanna W: Testing for HER2 status. Oncology 2001;61(suppl 2):22–30.
  24. Hayes DF, Bast R, Desch CE: A tumor marker utility grading system (TMUGS): a framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst 1996;88:1456–1466.
  25. Hayes DF, Trock B, Harris AL: Assessing the clinical impact of prognostic factors: when is ‘statistically significant’ clinically useful? Breast Cancer Res Treat 1998;52:305–319.
  26. Henson DE, Fielding P, Grignon DJ, Page DL, Hammond ME, Nash G, Pettigrew NM, Gorstein F, Hutter RV: College of American Pathologists Conference XXVI on clinical relevance of prognostic markers in solid tumors. Arch Pathol Lab Med 1995;19:1109–1112.
  27. Hortobagyi, GN: Developments in chemotherapy of breast cancer. Cancer 2000;88(suppl 12):3073–3079.
  28. Houston SJ, Plunkett TA, Barnes DM, Smith P, Rubens RD, Miles DW: Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer. Br J Cancer 1999;79:1220–1226.
  29. Hynes NE, Stern DF: The biology of erbB-2/neu/HER-2 and its role in cancer. Biochim Biophys Acta Rev Cancer 1994;1198:165–184.
  30. Hynes NE: Amplification and overexpression of the erbB-2 gene in human tumors: its involvement in tumor development, significance as a prognostic factor, and potential as a target for cancer therapy. Semin Cancer Biol 1993;4:19–26.

    External Resources

  31. Jarvinen TA, Tanner M, Rantanen V, Barlund M, Borg A, Grenman S, Isola J: Amplification and deletion of topoisomerase IIalpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. Am J Pathol 2000:156;839–847.
  32. Leitzel K, Teramoto Y, Konrad K, Chinchilli VM, Volas G, Grossberg H, Harvey H, Demers L, Lipton A: Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer. J Clin Oncol 1995;13:1129–1135.
  33. Leyland-Jones B, Smith I: Role of Herceptin® in primary breast cancer: Views from North America and Europe. Oncology 2001;61(suppl 2):83–91.
  34. Lipton A, Ali SM, Leitzel K, Chinchilli V, Engle L, Demers L, Brady C, Carney G, Cook B, Cambetas D, Allard J: Elevated serum HER-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer. Proc Am Soc Clin Oncol 2000;19:71A.
  35. Mass RD, Sanders C, Charlene K, Johnson L, Everett T, Anderson S: The concordance between the clinical trials assay (CTA) and fluorescence in situ hybridisation (FISH) in the Herceptin pivotal trials. Proc Am Soc Clin Oncol 2000;19:75A.
  36. McGuire WL: Breast cancer prognostic factors: evaluation guidelines. J Natl Cancer Inst 1991;83:1–9.
  37. Ménard S, Valagussa P, Pilotti S, Biganzoli E, Boracchi P, Casalini P, Tomasic G, Marubini E, Colnaghi MI, Cascinelli N, Bonadonna G: Benefit of CMF treatment in lymph node-positive breast cancer overexpressing HER2. Proc Am Soc Clin Oncol 1999;18:69A.
  38. Miles DW, Harris WH, Gillett CE, Smith P, and Barnes DM. Effect of c-erbB(2) and estrogen receptor status on survival in women with primary breast cancer treated with adjuvant cyclophosphamide/methotrexate/fluorouracil. Int J Cancer 1999;84:354–359.
  39. Nordenskjold B, Carstensen J, Rutqvist L, Stal O, Malmstrom P, Ferno M, Borg A, Bergh J, Bengtsson N, Hatschek T, Wallgren A: Prolonged follow-up of the Swedish randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer and relationships to hormone receptor and ERBB2 levels. Proc Am Soc Clin Oncol 2000;19:72A.
  40. Norton L, Slamon D, Leyland-Jones B, Wolter J, Fleming T, Eirmann W, Baselga J, Mendelsohn J, Bajamonde A, Ash M, Shak S: Overall survival (OS) advantage to Herceptin (H) in HER2-overexpressing (HER2+) metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 1999;18:127A.
  41. Paik S, Bryant J, Park C, Fisher B, Tan-Chiu E, Hyams D, Fisher ER, Lippman ME, Wickerham DL, Wolmark N: Erb-B2 and response to doxorubicin in patients with axillary lymph node-positive, hormone-receptor-negative breast cancer. J Natl Cancer Inst 1998;90:1361–1370.
  42. Pauletti G, Godolphin W, Press MF, Slamon DJ: Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene 1996;13:63–72.
  43. Petit T, Ghnassia J, Rodier J, Borel C, Escande A, Mors R, Janser J, Haegelé P: Relationship between erbB-2 status and neoadjuvant chemotherapy response is dependent on anthracycline dose intensity. Proc Am Soc Clin Oncol 2000;19:96A.
  44. Piccart M, Awada A, Hamilton A: Integration of new therapies into management of metastatic breast cancer: a focus on chemotherapy, treatment selection through use of molecular markers, and newly developed biologic therapies in late clinical development. Am Soc Clin Oncol 1999; 35th Annual Meeting, May 15–18, Atlanta, GA. Educational Book 526–39.
  45. Piccart MJ, Di Leo A, Hamilton A: HER2: a ‘predictive factor’ ready to use in the daily management of breast cancer patients? Eur J Cancer 2000;36:1755–1761.

    External Resources

  46. Ravdin PM, Green S, Albain KS, Boucher V, Ingle J, Pritchard K, Shepard L, Davidson N, Hayes DF, Clark GM, Martino S, Osborne CK, Allred DC: Initial report of the SWOG biological correlative study of C-erbB-2 expression as a predictor of outcome in a trial comparing adjuvant CAF T with tamoxifen (T) alone. Proc Am Soc Clin Oncol 1998;17:97A.
  47. Ries LAG, Kosary CL, Hankey BF, Miller BA, Clegg L, Edwards BK (eds): SEER Cancer Statistics Review, 1973–1996. Bethesda, National Cancer Institute, 1999.
  48. Ross JS, Fletcher JA: The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Stem Cells 1998;16:413–428.

    External Resources

  49. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177–182.
  50. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707–712.
  51. Slamon D, Leyland-Jones B, Shak S, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Baselga J, Norton L: Addition of HerceptinTM (humanized anti-HER2 antibody) to first-line chemotherapy for HER2 overexpressing metastatic breast cancer (HER2+/MBC) markedly increases anticancer activity: a randomized, multinational controlled phase III trial. Proc Am Soc Clin Oncol 1998;17:98A.
  52. Slamon D: N Eng J Med 2001, in press.
  53. Stål O, Sullivan S, Wingren S, Skoog L, Rutqvist LE, Carstensen JM, Nordenskjold B: c-erbB2 expression and benefit from adjuvant chemotherapy and radiotherapy of breast cancer. Eur J Cancer 1995;31A:2185–2190.
  54. Thor AD, Berry DA, Budman DR, Muss HB, Kute T, Henderson IC, Barcos M, Cirrincione C, Edgerton S, Allred C, Norton L, Liu ET: Erb-B2, p53 and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst 1998;90:1346–1360.
  55. van de Vijver MJ, Peterse JL, Mooi WJ, Wisman P, Lomans J, Dalesio O, Nusse R: Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma and limited prognostic value in Stage II breast cancer. N Engl J Med 1988;319:1239–1245.
  56. Vogel C, Cobleigh M, Tripathy D, Harris L, Fehrenbacher L, Slamon D, Ash M, Novotny W, Stewart S, Shak S: First-line, non-hormonal, treatment of women with HER2 overexpressing metastatic breast cancer with Herceptin (trastuzumab, humanized anti-HER2 antibody). Proc Am Soc Clin Oncol 2000;19:71A.
  57. Vona G, Caldini A, Sestini R, Rapi S, Bianchi S, Fanelli A, Pazzagli M, Orlando C: The c-erbB-2 oncogene amplification by competitive PCR in aneuploid cell clones flow sorted from breast cancer samples. Clin Chem Lab Med 1999;37:649–654.
  58. Wright C, Nicholson S, Angus B, Sainsbury JF, Farndon J, Cairns J, Harris AL, Horne CH: Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer. Br J Cancer 1992;65:118–121.
  59. Yamauchi H, O’Neill A, Gelman R, Carney W, Tenney DY, Hosch S, Hayes DF: Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein. J Clin Oncol 1997;15:2518–2525.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50